Orange Book product · Brand (NDA)
SECUADO
ASENAPINE
At a glance
Oct 11, 2019
Approved
Brand (NDA)
Application
Not listed
TE code
6
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Oct 11, 2019
6 yr 9 mo ago
Today
Patent 10022445 expires
Listed drug product patent expiration.
Jul 25, 2033
in 7 yr 2 mo
Patent 10583121 expires
Listed drug product patent expiration.
Jul 25, 2033
in 7 yr 2 mo
Patent 10814002 expires
Listed drug product patent expiration.
Jul 25, 2033
in 7 yr 2 mo
Patent 11123305 expires
Listed drug product patent expiration.
Jul 25, 2033
in 7 yr 2 mo
Patent 9687474 expires
Listed drug product patent expiration.
Jul 25, 2033
in 7 yr 2 mo
Patent 11813364 expires
Listed drug product patent expiration.
Sep 22, 2033
in 7 yr 4 mo
Pharmaceutical detail
Active ingredient
ASENAPINE
Strength
3.8MG/24HR
Dosage form
SYSTEM
Route
TRANSDERMAL
TE code
Not listed
Application
NDA 212268
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Listed patents (6)
| Patent | Expires | In | Type |
|---|---|---|---|
| 10022445 | Jul 25, 2033 | in 7 yr 2 mo | Product |
| 10583121 | Jul 25, 2033 | in 7 yr 2 mo | ProductU-2763 |
| 10814002 | Jul 25, 2033 | in 7 yr 2 mo | ProductU-2763 |
| 11123305 | Jul 25, 2033 | in 7 yr 2 mo | Product |
| 9687474 | Jul 25, 2033 | in 7 yr 2 mo | Product |
| 11813364 | Sep 22, 2033 | in 7 yr 4 mo | Product |
